All In Biotech

Drug Trial Radar · NCT05443984

JP-1366 20mg Versus Esomeprazole 40mg in Patients With Erosive Esophagitis

A Randomized, Double-blind, Parallel, Active-controlled, Non-inferiority, Phase III Multiple Center Clinical Trial to Compare the Efficacy and Safety of JP-1366 20 mg Versus Esomeprazole 40 mg in Patients With Erosive Esophagitis

Last checked: Nov 19, 2026Latest source record: Aug 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Jan 17, 2022

Primary completion

Jan 5, 2023

Study completion Jan 5, 2023

Sponsor

Lead sponsor
Onconic Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jul 5, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of JP-1366 20 mg compared to esomeprazole 40 mg in patients with erosive esophagitis

Conditions

  • Erosive Esophagitis

Interventions

  • JP-1366 20mgDrug

    1 capsule of JP-1366 20 mg, 1 tablet of esomeprazole placebo (irrespective of meals)

  • Esomeprazole 40mgDrug

    1 capsule of JP-1366 placebo, 1 tablet of esomeprazole 40 mg placebo (irrespective of meals)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The cumulative healing rate of mucosal break at 8-week after the investigational product administration (%)Time frame: Week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Asan Medical Center and 26 hospitals

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.